Additionally, MRIGlobal will assess the NIAID laboratory network capabilities to accurately and reliably perform study-specific Mtb tests. If any deficiencies are identified, MRIGlobal will advise and train laboratory and clinical site staff.
"We are honored to support NIAID in its research to better understand the development of Tuberculosis drug resistance," said Roger K. Harris, Ph.D., MRIGlobal Vice President. "The opportunity builds upon our ongoing expertise in global health as it relates to detecting, preventing, and responding to infectious disease and antimicrobial resistance."
Tuberculosis (TB) is a contagious and often severe airborne disease caused by infection with Mycobacterium tuberculosis bacteria. TB typically affects the lungs, but it can also affect any other organ of the body, and continues to be one of the major causes of disability and death worldwide.
MRIGlobal, a not-for-profit research and development organization, delivers global solutions in national security and defense, energy and environment, life and animal sciences, agriculture and food safety, and transportation. The organization performs scientific research, advanced engineering and program integration and management for clients in government, industry and academia. Established in 1944 as Midwest Research Institute, MRIGlobal is based is one of two partners in the Alliance for Sustainable Energy, LLC, which manages and operates the National Renewable Energy Laboratory (NREL) in Golden, Colo., for the U.S. Department of Energy. For more information, visit mriglobal.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mriglobal-wins-137m-nihniaid-quality-assessment-contract-for-mycobacterium-tuberculosis-300399849.html